5-OxoETE Receptor Blocking Pepti

Confirm delete?

5-OxoETE Receptor Blocking Peptide

Cat No: 10006618

Antibodies - Blocking Peptides

To be used in conjunction with Cayman’s 5-OxoETE Receptor Polyclonal Antibody (Item No. 100025) to block protein-antibody complex formation during immunochemical analysis of 5-OxoETE. The 5-OxoETE receptor recognizes eicosatetraenoic acids and polyunsa...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

antibodies western blotting blots signaling signalling WB ICC immunocytochemistry 5-oxo-ETE receptors controls peptides proteins eicosatetraenoic acids PUFAs polyunsaturated fatty

Product Overview:
To be used in conjunction with Cayman’s 5-OxoETE Receptor Polyclonal Antibody (Item No. 100025) to block protein-antibody complex formation during immunochemical analysis of 5-OxoETE. The 5-OxoETE receptor recognizes eicosatetraenoic acids and polyunsaturated fatty acids including 5-Oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-OxoETE), which is the most potent ligand.{11953} 5-OxoETE is a potent stimulator of chemotaxis for eosinophils and neutrophils that mediates its action via a putative G-protein coupled receptor (GPCR).{10476,11003} The receptor couples to Gi/o to inhibit cyclic AMP production and to mobilize intracellular calcium.{10476,11003} Northern blot analysis reveals that the receptor is highly expressed on eosinophils and neutrophils, suggesting a key role in the inflammatory response.{11003} In addition, the protein can also be detected in tissues such as kidney and liver.{10476,11003}

Size	1 ea
Shipping	dry ice
Formulation	200 µg of peptide in 200 µl TBS, pH 7.4, containing 0.1% BSA and 0.02% sodium azide
Custom Code	3504.00
UNSPSC code	41105329

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.